# Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

> **NCT02204098** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma
- Malignant Neoplasm of Breast

## Interventions

- **BIOLOGICAL:** Mammaglobin-A DNA Vaccine
- **PROCEDURE:** Optional biopsy

## Key facts

- **NCT ID:** NCT02204098
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01-07
- **Primary completion:** 2022-04-06
- **Final completion:** 2028-08-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- Rising Tide Foundation
- United States Department of Defense

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204098, "Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02204098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*